Journal ArticleDOI
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Reads0
Chats0
About:
This article is published in Yearbook of Oncology.The article was published on 2010-01-01. It has received 850 citations till now. The article focuses on the topics: Dasatinib & Imatinib.read more
Citations
More filters
Journal ArticleDOI
Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.
Koiti Inokuchi,Kazutaka Nakayama,Tetsuzo Tauchi,Tomoiku Takaku,Norio Yokose,Hiroki Yamaguchi,Takashi Kumagai,Norio Komatsu,Kazuma Ohyashiki +8 more
TL;DR: The clinical responses to thyrosine kinase inhibitors (TKIs) and the molecular and cytogenetic characteristics of 18 chronic myeloid leukemia (CML) patients with 3-way chromosomal translocations and the overall survival was 100 months in 56% of the patients.
Journal ArticleDOI
Monitoring molecular response to tyrosine kinase therapy in chronic myelogenous leukemia.
TL;DR: The ever-expanding menu of TKIs for CML is reviewed and Dr. Jerald Radich's thoughts on resolving the clinical questions regarding when to start which drugs, how to sequence the drugs, and how best to decide when to change the therapeutic tack are shared.
Dissertation
Mechanisms determining efficacy of tyrosine kinase-targeting anti-cancer drugs
TL;DR: This thesis tries to explain some mechanisms lying behind the sensitivity or the resistance to new targeted therapies of two cancer types: glioblastoma (GBM) and colorectal cancer (CRC).
Journal ArticleDOI
NCCN and ELN: What do the guidelines tell us?
TL;DR: With adherence to the recommendations proposed by the NCCN and ELN, the authors can expect to continue to see excellent outcomes for their patients with CML.
Journal ArticleDOI
Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia
George Ansstas,Ravi Vij +1 more
TL;DR: It is proposed that adherence to definitions of progression from the European LeukmiaNet may aid future research and therapeutic decision-making.
References
More filters
Journal ArticleDOI
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop M. Kantarjian,Neil P. Shah,Andreas Hochhaus,Jorge E. Cortes,Sandip Shah,Manuel Ayala,Beatriz Moiraghi,Zhixiang Shen,Jiri Mayer,Ricardo Pasquini,Hirohisa Nakamae,Françoise Huguet,Concepción Boqué,Charles Chuah,Eric Bleickardt,M. Brigid Bradley-Garelik,Chao Zhu,Ted Szatrowski,David Shapiro,Michele Baccarani +19 more
TL;DR: Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long- term outcomes among patients with newly diagnosed chronic-phase CML.